Difference between revisions of "IDH-1"
Jump to navigation
Jump to search
Jensflorian (talk | contribs) |
Jensflorian (talk | contribs) (update) |
||
| Line 33: | Line 33: | ||
*Neuronal tumors | *Neuronal tumors | ||
*Sarcoma, carcinoma <ref>{{Cite journal | last1 = Sahm | first1 = F. | last2 = Capper | first2 = D. | last3 = Meyer | first3 = J. | last4 = Hartmann | first4 = C. | last5 = Herpel | first5 = E. | last6 = Andrulis | first6 = M. | last7 = Mechtersheimer | first7 = G. | last8 = Petersen | first8 = I. | last9 = Paulus | first9 = W. | title = Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. | journal = Histopathology | volume = 58 | issue = 7 | pages = 1167-72 | month = Jun | year = 2011 | doi = 10.1111/j.1365-2559.2011.03823.x | PMID = 21707716 }}</ref> | *Sarcoma, carcinoma <ref>{{Cite journal | last1 = Sahm | first1 = F. | last2 = Capper | first2 = D. | last3 = Meyer | first3 = J. | last4 = Hartmann | first4 = C. | last5 = Herpel | first5 = E. | last6 = Andrulis | first6 = M. | last7 = Mechtersheimer | first7 = G. | last8 = Petersen | first8 = I. | last9 = Paulus | first9 = W. | title = Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. | journal = Histopathology | volume = 58 | issue = 7 | pages = 1167-72 | month = Jun | year = 2011 | doi = 10.1111/j.1365-2559.2011.03823.x | PMID = 21707716 }}</ref> | ||
==Functional meaning== | |||
The R132H amino acic exchange alters the enzymatic activity of IDH resulting in production D-2-hydroxyglutarate (D-2HG).<ref>{{Cite journal | last1 = Longuespée | first1 = R. | last2 = Wefers | first2 = AK. | last3 = De Vita | first3 = E. | last4 = Miller | first4 = AK. | last5 = Reuss | first5 = DE. | last6 = Wick | first6 = W. | last7 = Herold-Mende | first7 = C. | last8 = Kriegsmann | first8 = M. | last9 = Schirmacher | first9 = P. | title = Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. | journal = Acta Neuropathol Commun | volume = 6 | issue = 1 | pages = 21 | month = 03 | year = 2018 | doi = 10.1186/s40478-018-0523-3 | PMID = 29499756 }}</ref> Therefore the mutated enzyme is considered an oncometabolite. | |||
[[File:Wild-type_and_mutant_IDH1_structures.png|400px]] | |||
Revision as of 14:05, 14 March 2018
IDH1 staining in oligodendroglioma.
Isocitrate dehydrogenase 1 (R132H), often abbreviated IDH1 or IDH-1 is a mutation-specific antibody detecting the R132H mutation in tumor material.[1]
Positive staining
- Cytoplasmic[2]
- Does not stain endothelial cells and inflammatory cells.
IDH-1 (R132H) in a secondary glioblastoma
IDH-1 in a oliogoastrocytoma grade II
Absence of IDH-1 in a primary glioblastoma
Note:
- The antibody does not detect other rare IDH-1/2 mutations (ie. R132G or R172K).
Normal tissues
- Absent
Tumours
Negative
Negative staining:[5]
- Non-tumorous tissue, endothelial cells.
- Ependymoma
- Pilocytic astrocytoma
- Neuronal tumors
- Sarcoma, carcinoma [6]
Functional meaning
The R132H amino acic exchange alters the enzymatic activity of IDH resulting in production D-2-hydroxyglutarate (D-2HG).[7] Therefore the mutated enzyme is considered an oncometabolite.
See also
References
- ↑ Capper, D.; Zentgraf, H.; Balss, J.; Hartmann, C.; von Deimling, A. (Nov 2009). "Monoclonal antibody specific for IDH1 R132H mutation.". Acta Neuropathol 118 (5): 599-601. doi:10.1007/s00401-009-0595-z. PMID 19798509.
- ↑ Capper, D.; Weissert, S.; Balss, J.; Habel, A.; Meyer, J.; Jäger, D.; Ackermann, U.; Tessmer, C. et al. (Jan 2010). "Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.". Brain Pathol 20 (1): 245-54. doi:10.1111/j.1750-3639.2009.00352.x. PMID 19903171.
- ↑ Capper, D.; Reuss, D.; Schittenhelm, J.; Hartmann, C.; Bremer, J.; Sahm, F.; Harter, PN.; Jeibmann, A. et al. (Feb 2011). "Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.". Acta Neuropathol 121 (2): 241-52. doi:10.1007/s00401-010-0770-2. PMID 21069360.
- ↑ Andrulis, M.; Capper, D.; Luft, T.; Hartmann, C.; Zentgraf, H.; von Deimling, A. (Aug 2010). "Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.". Leuk Res 34 (8): 1091-3. doi:10.1016/j.leukres.2010.02.014. PMID 20227112.
- ↑ Capper, D.; Reuss, D.; Schittenhelm, J.; Hartmann, C.; Bremer, J.; Sahm, F.; Harter, PN.; Jeibmann, A. et al. (Feb 2011). "Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.". Acta Neuropathol 121 (2): 241-52. doi:10.1007/s00401-010-0770-2. PMID 21069360.
- ↑ Sahm, F.; Capper, D.; Meyer, J.; Hartmann, C.; Herpel, E.; Andrulis, M.; Mechtersheimer, G.; Petersen, I. et al. (Jun 2011). "Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation.". Histopathology 58 (7): 1167-72. doi:10.1111/j.1365-2559.2011.03823.x. PMID 21707716.
- ↑ Longuespée, R.; Wefers, AK.; De Vita, E.; Miller, AK.; Reuss, DE.; Wick, W.; Herold-Mende, C.; Kriegsmann, M. et al. (03 2018). "Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry.". Acta Neuropathol Commun 6 (1): 21. doi:10.1186/s40478-018-0523-3. PMID 29499756.